1. Home
  2. DOMH vs GLTO Comparison

DOMH vs GLTO Comparison

Compare DOMH & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • GLTO
  • Stock Information
  • Founded
  • DOMH 1967
  • GLTO 2011
  • Country
  • DOMH United States
  • GLTO Denmark
  • Employees
  • DOMH N/A
  • GLTO N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • GLTO Health Care
  • Exchange
  • DOMH Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • DOMH 8.8M
  • GLTO 6.5M
  • IPO Year
  • DOMH N/A
  • GLTO 2020
  • Fundamental
  • Price
  • DOMH $3.02
  • GLTO $4.71
  • Analyst Decision
  • DOMH
  • GLTO Buy
  • Analyst Count
  • DOMH 0
  • GLTO 1
  • Target Price
  • DOMH N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • DOMH 427.5K
  • GLTO 17.6K
  • Earning Date
  • DOMH 03-31-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • DOMH N/A
  • GLTO N/A
  • EPS Growth
  • DOMH N/A
  • GLTO N/A
  • EPS
  • DOMH N/A
  • GLTO N/A
  • Revenue
  • DOMH $12,589,000.00
  • GLTO N/A
  • Revenue This Year
  • DOMH N/A
  • GLTO N/A
  • Revenue Next Year
  • DOMH N/A
  • GLTO N/A
  • P/E Ratio
  • DOMH N/A
  • GLTO N/A
  • Revenue Growth
  • DOMH 1117.50
  • GLTO N/A
  • 52 Week Low
  • DOMH $0.83
  • GLTO $4.40
  • 52 Week High
  • DOMH $4.35
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 65.22
  • GLTO 45.14
  • Support Level
  • DOMH $2.86
  • GLTO $4.70
  • Resistance Level
  • DOMH $4.35
  • GLTO $5.11
  • Average True Range (ATR)
  • DOMH 0.52
  • GLTO 0.38
  • MACD
  • DOMH 0.14
  • GLTO -0.01
  • Stochastic Oscillator
  • DOMH 53.19
  • GLTO 26.23

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: